← Leaderboards
Lori Jean Van Orden
Blackthorn Therapeutics, Inc.
$1,617,097
Attributed
$1,617,097
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.2M · FY2017–20$2M$1.5M$1M$500K$0
'17
'18
'19
'20
Funding mix
By agency
NIH$1,617,097 · 1
By mechanism
UH3$1,617,097 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Adult”
- Beth Baseler · Leidos Biomedical Research, Inc.$127,607,354
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$93,592,175
- Susan M Landau · University Of California Berkeley$47,252,026
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$42,295,422
- Nancy Roche · Leidos Biomedical Research, Inc.$39,999,252
- Evan Z Macosko · Broad Institute, Inc.$32,116,761
Research focus
AdultChronic Daily HeadachesAffectAllodyniaCharacteristicsAminesAmygdaloid StructureAnalgesic Overuse HeadachesAnalogAnimal ModelAcuteCerebrospinal FluidAurasBehaviorBiological Adaptation To StressBiological AvailabilityBloodBrainBrain RegionCategoriesCell Membrane PermeabilityCentral SensitizationCephalicClassic Migraine
Grant awards (4)
Discovery of non-addictive KOR antagonists for migraine prophylaxis$110,635
UH3 · FY2020 · NS · contact PI
Discovery of non-addictive KOR antagonists for migraine prophylaxis$139,735
UH3 · FY2019 · NS · contact PI
Discovery of non-addictive KOR antagonists for migraine prophylaxis$129,735
UH3 · FY2018 · NS · contact PI
Discovery of non-addictive KOR antagonists for migraine prophylaxis$1,236,992
UH3 · FY2017 · NS · contact PI